Shares of Health Care sector company BioMarin Pharmaceutical moved -17.5% today, and are now trading at a price of $70.06. The Large-Cap stock's daily volume was 8,169,682 compared to its average volume of 2,056,537. The S&P 500 index returned a 0.0% performance.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company is based in San Rafael and has 3,401 full time employees. Its market capitalization is $13,338,232,832.
24 analysts are following BioMarin Pharmaceutical and have set target prices ranging from $72.0 to $139.0 per share. On average, they have given the company a rating of buy. At today's prices, BMRN is trading -36.33% away from its average analyst target price of $110.03 per share.
Over the last year, BMRN shares have gone down by -4.2%, which represents a difference of -30.5% when compared to the S&P 500. The stock's 52 week high is $99.56 per share and its 52 week low is $69.6. With average free cash flows of $12.72 Million that have been growing at an average rate of 9.4% over the last 5 years, BioMarin Pharmaceutical declining stock performance may not be reflective of the quality of its underlying business.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 159,259 | 96,691 | 62,568 | 13.88 |
| 2022 | 175,902 | 120,959 | 54,943 | -73.71 |
| 2021 | 304,536 | 95,578 | 208,958 | 821.86 |
| 2020 | 85,365 | 114,312 | -28,947 | 70.08 |
| 2019 | 48,262 | 145,026 | -96,764 | 22.22 |
| 2018 | 20,208 | 144,620 | -124,412 |
